US 2017/0360784 A1 · TRIZOL-1-OL ANALOGS ANTI-RETROVIRAL LATENCY DRUGS

Abstract

In one aspect, the invention relates to triazol-1-ol compounds, analogs thereof, compositions comprising same, and methods of using same, alone or in combination with other agents, to reactivate latent retroviruses, and more particularly to reactivate latent HIV-1. Such compounds, compositions, and methods can be used, for example, in connection with diagnosing and/or treating a retrovirus, and more specifically HIV-1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claims26

Dependent claims

A method of activating a latent retrovirus in a subject, the method comprising the step of administering to the subject an effective amount of a compound represented by a formula:

wherein n is 0 or 1;
wherein R1 is selected from H, C1-C4 alkyl, C1-C6 aryl, C(O)Ar, C(O)N(CH3)2, SO2N(CH3)2, fluorenylmethyloxycarbonyl, N-((dimethylamino)methylene)-N-methylmethanaminium tetrafluoroborate, N-((dimethylamino)methylene)-N-methylmethanaminium hexafluorophosphate (V), tri(pyrrolidin-1-yl)phosphonium hexafluorophosphate (V), tris(dimethylamino)phosphonium hexafluorophosphate (V), 1-(pyrrolidin-1-ylmethylene)pyrrolidin-1-ium hexafluorophosphate (V), and 1-(piperidin-1-ylmethylene)piperidin-1-ium hexafluorophosphate (V);
wherein R2 is selected from H and C1-C4 alkyl;
and
wherein R3 is selected from H and C1-C4 alkyl;
or wherein R2 and R3 are covalently bonded and, together with the intermediate atoms, comprise an optionally substituted fused six-membered aryl or heteroaryl ring.

3 more elements

Dependencies are inferred from the claim text.

Trizol-1-ol analogs anti-retroviral latency drugs

Life of this patent

Trizol-1-ol analogs anti-retroviral latency drugs

Life of this patent

Abstract

Claims26